- Home
- CRDF
as 12-17-2024 4:00pm EST
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 133.5M | IPO Year: | N/A |
| Target Price: | $10.33 | AVG Volume (30 days): | 3.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $6.42 | Next Earning Date: | 11-07-2024 |
| Revenue: | $688,000 | Revenue Growth: | 49.57% |
| Revenue Growth (this year): | 23.78% | Revenue Growth (next year): | -45.63% |
Stock Insider Trading Activity of Cardiff Oncology Inc. (CRDF)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| TANNENBAUM RENEE P | CRDF | Director | Dec 12 '24 | Buy | $3.42 | 10,000 | $34,224.00 | 20,000 | |
| PACE GARY W | CRDF | Director | Dec 11 '24 | Buy | $2.60 | 361,615 | $940,199.00 | 1,047,876 |
Latest Cardiff Oncology Inc. News
CRDF Breaking Stock News: Dive into CRDF Ticker-Specific Updates for Smart Investing
TipRanks
4 days ago
Cardiff Oncology price target raised to $10 from $7 at Piper Sandler
TipRanks
7 days ago
Cardiff Oncology Reports Promising Phase 2 Trial Results
GlobeNewswire
8 days ago
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
GlobeNewswire
8 days ago
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
GlobeNewswire
a month ago
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
Simply Wall St.
a month ago
Cardiff Oncology Third Quarter 2024 Earnings: Beats Expectations
GlobeNewswire
a month ago
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
GlobeNewswire
2 months ago
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
Compare CRDF vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRDF Cardiff Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.